Mylan NV (MYL) Launches Generic Version Of Pfizer Inc. (PFE)’s Unasyn


Mylan NV (NASDAQ:MYL) has launched the generic version of Pfizer Inc. (NYSE:PFE)’s Unasyn, i.e. Ampicillin, as well as, Sulbactam for Injection in the United States. The company got the final approval from the FDA for its NDA for these products. These drugs are meant for infections treatment. That is arising out of susceptible strains of selected microorganisms in the skin, as well as, skin structure infections, gynecological infections, and intra-abdominal infections.

Drug Sales In US

IMS Health said that pharmacy bulk package, which included Ampicillin and Sulbactam, recorded sales of about $29 million for the one-year period ending June. Mylan NV (NASDAQ:MYL)’s unveiling of these products add to its growing portfolio list of over 145 injectable products that are available to the patients in the Americas in a variety of therapeutic categories that included anesthesia/pain management, cardiovascular, anti-infectives, and oncology.

The company has 262 ANDAs currently pending with the regulator for approval. That accounted for $99.3 billion of brand sales annually based on the IMS Health estimation. Of these, fifty ANDAs have the possibility of first-to-file opportunities. That will account for $33.4 billion of brand sales annually for the year ended December, which was also based on IMS Health estimation.

Committed To Setting New Standards

Mylan NV (NASDAQ:MYL) said that it was committed to set fresh standards in healthcare and is working to offer seven billion people to access to high-quality medicine. The company made it clear that its innovation was meant to satisfy the unmet requirements and make reliability, as well as, service excellence a habit.

The drug maker said that it provided a growing portfolio of approximately 1,400 generic pharmaceuticals apart from a number of branded medications. Aside from those, Mylan NV (NASDAQ:MYL) offered an extensive range of antiretroviral therapies. Significantly, half of the HIV/AIDs patients were dependent on it in the developing nations. The company is marketing its products in about 145 countries, as well as, territories.

Viraj Shah

Viraj Shah has completed M.Com (Finance) and is currently pursuing his CFP. He tracks US markets along with other global markets like India very closely. He is very passionate about stocks, real estate, and technology. He also believes that money can always be made in the market.

You may also like...

More in MYL
Mylan logo
Perrigo Company plc Ordinary Shares (PRGO) Stays Hostile In Mylan NV (MYL)’s Bid

The war of words between Perrigo Company plc Ordinary Shares (NYSE:PRGO) and Mylan NV (NASDAQ:MYL) appears to be heating up...

Close